IQV VS EW Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

IQV
91/100

IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.

EW
10/100

EW returned -13.68% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

IQV
69/100

17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.

EW
75/100

21 analysts offer 12-month price targets for EW. Together, they have an average target of 114.24, the most optimistic target put EW at 140 within 12-months and the most pessimistic has EW at 75.

Technicals

IQV
75/100

IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

EW
10/100

EW receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

IQV
100/100

IQV has missed earnings 0 times in the last 20 quarters.

EW
10/100

EW has missed earnings 5 times in the last 20 quarters.

Profit

IQV
88/100

Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.

EW
74/100

Out of the last 20 quarters, EW has had 19 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

IQV
49/100

IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

EW
52/100

EW has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

IQVIA Holdings Inc. Summary

New York Stock Exchange / IQV
Healthcare
Medical - Diagnostics & Research
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Edwards Lifesciences Corp Summary

New York Stock Exchange / EW
Healthcare
Medical - Devices
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.